Introduction, Radiobiology I, and Chemistry

In the first session, presenters introduce the curriculum, radiopharmaceutical therapies (RPTs) in general, radiobiology of RPTs, and chemistry of RPTs. This includes discussion of pharmacokinetics, biodistribution, dose rate, subcellular targeting, molecular and cellular effects of beta/alpha emitters, deterministic and stochastic effects, and toxicities.

Topics:

  • Introduction to Radiopharmaceutical Therapy and Curriculum Overview - Ana Kiess, MD, PhD
  • Radiobiology I (PK, Biodistribution, Dose Rate, Subcellular Targeting, Molecular and Cellular Effects of Beta/Alpha, Deterministic and Stochastic Effects, Toxicities) - Ana Kiess, MD, PhD
  • Chemistry of Radiopharmaceutical Therapies for Medical Use - Freddy E. Escorcia, MD, PhD

Target Audience

This activity is designed to meet the interests of radiation oncologists, radiation physicists, radiation biologists, radiation therapists, diagnostic radiologists, medical oncologists and radiation oncology residents.

Learning Objectives

Upon completion of this activity, participants should be able to do the following:

  • Discuss the relevant principles of physics, chemistry and radiobiology for radiopharmaceutical therapies (RPTs).
  • Identify clinical indications and therapy-specific management for RPTs that are currently approved for clinical use.
  • Identify barriers and logistical steps for implementing RPT use in one's own practice.
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 2.00 Certificate of Attendance
    This activity was designated for 2.00 AMA PRA Category 1 Credit™.
Course opens: 
03/27/2024
Course expires: 
07/04/2026
Cost:
$0.00
Part of: 
Beyond the Beam: A Radiation Oncology Curriculum for Radiopharmaceutical Therapy
Rating: 
0
  • Ana Kiess, MD, PhD, is employed by Johns Hopkins University. Dr. Kiess receives grant/research funding from Bayer and serves in an uncompensated consultant role with Novartis/AAA.
  • Freddy E. Escorcia, MD, PhD, is employed by the National Cancer Institute. 

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 2.00 Certificate of Attendance
    This activity was designated for 2.00 AMA PRA Category 1 Credit™.

Price

Cost:
$0.00
Please login or register to take this course.